Anika Therapeutics, Inc.

As of May 5, 2022, Anika Therapeutics, Inc. is considered overvalued and risky due to negative earnings, poor financial metrics, and a year-to-date stock performance decline of 45.69%, significantly underperforming the S&P 500.

As of May 5, 2022, Anika Therapeutics, Inc. is considered overvalued with a risky valuation grade due to negative performance metrics, including a Price to Book Value of 1.10, an EV to Sales ratio of 0.81, and significant losses reflected in its low ROCE of -30.70% and ROE of -22.47%, alongside a year-to-date stock decline of 33.66%.

As of June 11, 2025, Anika Therapeutics, Inc. is in a bearish trend, supported by bearish MACD signals, moving averages, and Bollinger Bands across multiple time frames, indicating continued bearish momentum.

As of March 2022, Anika Therapeutics, Inc.'s management team includes Dr. Joseph Bower as Independent Chairman and Dr. Cheryl Blanchard as President and CEO, along with several Independent Directors on the Board.

Anika Therapeutics, Inc. is a joint preservation company specializing in early intervention orthopedic care, with recent net sales of $26 million and a market cap of $158.19 million. The company reported a net loss of $4 million and has a negative return on equity of -22.47%.

As of Jun 18, Anika Therapeutics, Inc. has a market capitalization of 158.19 million and reported net sales of 137.44 million with a net profit of -36.46 million over the latest four quarters.